

PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT STUDY TO ASSESS THE BURDEN OF HERPES ZOSTER DISEASE IN THE EYE: BASELINE RESULTS OF INITIAL PATIENTS

Laura T. Pizzi^{1*}, Benjamin Leiby², David Chu³, Emily W. Gower⁴, Haresh Ailani⁵, Joseph P. Shovlin⁶, Katherine M. Prioli¹, Soham Shukla¹, Brandon J. Patterson⁷, Deborah Rausch⁷, Philip O. Buck⁷, Ann P. Murchison⁸

¹Rutgers University, Piscataway, NJ, USA; ²Thomas Jefferson University, Philadelphia, PA, USA; ³Metropolitan Eye Research and Surgery Institute, Palisades Park, NJ, USA; ⁴Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA; ⁵Eye Consultants of Northern Virginia, Springfield, VA, USA; ⁶Northeastern Eye Institute, Scranton, PA, USA; ⁷GSK, Philadelphia, PA, USA; ⁸Wills Eye Hospital, Philadelphia, PA, USA; *Presenting author: Laura Pizzi, laura.pizzi@rutgers.edu

BACKGROUND


- With about 1 million cases of herpes zoster in the US annually, approximately 10-20% are complicated by herpes zoster ophthalmicus (HZO),¹ many of which have ocular involvement that can lead to vision threatening complications.²
- Objectives: describe the frequency, duration, and impact of HZO complications; and vision-specific health-related quality of life and depressive symptoms in acute HZO patients.

METHODS

- This ongoing, 1-year, prospective, multicenter (6 major US ophthalmology practices), observational cohort study aims to recruit 300 patients; herein, we report diagnoses and baseline patient-reported outcomes for the first 13 patients.

RESULTS

Patients' ocular diagnoses and self-reported pain and symptoms




Other ocular diagnosis: n=6; other herpes zoster ophthalmicus disease: n=3; other ocular problems: n=9. HZ, herpes zoster. Patients may have more than one ocular symptom/diagnosis, thus the total may be >13. Symptoms are not mutually exclusive or specific to one eye.

CONCLUSIONS

- This study represents initial patients' data from the first large-scale effort to quantify HZO burden.
- These preliminary data show that HZO commonly has an impact on the eye, including pain and other self-reported outcomes.
- Ultimately, the findings may be used to help develop a formal patient-reported symptom scale for use in research and clinical practice.


Patient selection & study design



Demographic characteristics

- 11/13 Women
- 13/13 Medical insurance (10/13 Medicare)
- 9/13 Retired
- 7/13 College graduates (or other degree)
- Mean age: 71 years

Patients' self-reported outcomes



For NEI-VFQ-25 (National Eye Institute 25-item Visual Function Questionnaire), only mean scores <75 are shown; scores range: 0 – 100. ZBPI (Zoster Brief Pain Inventory) scores range: 0 – 10. PHQ-8 (eight-item Patient Health Questionnaire depression scale) scores range: 0 – 24. Data is represented as mean score ± standard deviation.



- Herpes zoster ophthalmicus is associated with eye pain and other eye symptoms.
- Herpes zoster ophthalmicus may affect quality of life.

Funding: GlaxoSmithKline Biologicals SA (GSK study identifiers: 209235/HO-17-17967)

